CTOs on the Move

Medocity

www.medocity.com

 
Medocity is a leading healthcare tech and services company specializing in digital care solutions to deliver optimized, continuous care between visits.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.medocity.com
  • 1 Upper Pond Road Building D, Floor 3
    Parsippany, NJ USA 07054
  • Phone: 973.679.8240

Executives

Name Title Contact Details

Funding

Medocity raised $10.8M on 12/17/2020

Similar Companies

United Medical Solutions

United Medical Solutions is a Idaho Falls, ID-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Long Beach Prescription Pharmacy

Long Beach Prescription Pharmacy is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Newport Beach, CA. To find more information about Long Beach Prescription Pharmacy, please visit www.ipmrx.com

Fayette Companies

Fayette Companies is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Peoria, IL. To find more information about Fayette Companies, please visit www.fayettecompanies.org

Laurel Health System

Laurel Health System is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Laurel Health System is based in Wellsboro, PA. You can find more information on Laurel Health System at www.laurelhs.org

Accord BioPharma

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.